Tau oligomers as target for novel Alzheimer’s disease diagnostics and therapeutics KU Leuven
With the higher life expectancy, the incidence of neurodegenerative diseases, such as Alzheimer’s disease (AD), rises rapidly. In 2010, an estimated 35.6 million people worldwide were suffering from dementia, with AD representing 50 to 80% of the cases. It is predicted that the overall number of patients with dementia will double every twenty years in the absence of disease-modifying therapies. The existing drugs for AD offer poor therapeutic ...